CANDEL THERAPEUTICS
Candel develops cancer immunotherapies designed to improve the lives of cancer patients and their families. The company's immunotherapies focus on preventing the recurrence and progression of cancer with low toxicity level which is well suited for the treatment of less aggressive or slower growing cancers such as newly diagnosed prostate cancer, enabling physicians to ensure improved outcomes for their patients and help them recover faster.
CANDEL THERAPEUTICS
Industry:
Biotechnology Genetics Health Care Health Diagnostics Medical Therapeutics
Founded:
1999-01-01
Address:
Needham, Massachusetts, United States
Country:
United States
Website Url:
http://www.candeltx.com
Total Employee:
11+
Status:
Active
Contact:
6179165445
Total Funding:
164.9 M USD
Technology used in webpage:
Domain Not Resolving Microsoft Exchange Online Microsoft Azure DNS GoDaddy DNS Cloudflare Hosting Campaign Monitor Campaign Monitor Widget
Similar Organizations
ACEA Therapeutics
ACEA Therapeutics develops and delivers innovative treatments to improve the lives of patients with life-threatening diseases.
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Denali Therapeutics
Denali Therapeutics is dedicated to defeating neurodegenerative diseases to deliver safe and effective medicines to patients and families.
Grail
Grail develops a pan-cancer screening test designed to detect cancers at an early stage.
IRX Therapeutics
IRX Therapeutics develops immune therapies designed to activate a patient’s immune system to defeat cancer and related diseases.
Link Immunotherapeutics
Link Immunotherapeutics develops therapies with a focus on known cancer targets and bispecific architectures.
Medtronic
Medtronic develops and manufactures medical device technologies and therapies to treat chronic diseases worldwide.
NeoGenomics
NeoGenomics is a cancer reference laboratory that provides cancer testing and partnership programs to pathologists and oncologists.
ProCure Treatment Centers
ProCure Treatment Centers develops and operates a network of proton therapy centers in cities of the United States.
Current Advisors List
Board_member
2020-01-01
Advisor
Current Employees Featured
Estuardo Aguilar-Cordova Chairman and Chief Executive Officer @ Candel Therapeutics
Chairman and Chief Executive Officer
1999-01-01
Laura K. Aguilar Chief Medical Officer @ Candel Therapeutics
Chief Medical Officer
2016-01-01
Stephen Rocamboli Chief Business Officer @ Candel Therapeutics
Chief Business Officer
2015-04-01
Daniel Giroux Vice-President of Manufacturing @ Candel Therapeutics
Vice-President of Manufacturing
2016-08-01
Nathan Caffo Chief Business Officer @ Candel Therapeutics
Chief Business Officer
2020-09-01
Jason A. Amello Chief Financial Officer @ Candel Therapeutics
Chief Financial Officer
2022-09-01
Garrett Nichols Chief Medical Officer @ Candel Therapeutics
Chief Medical Officer
2022-01-01
Paul-Peter Tak President & CEO @ Candel Therapeutics
President & CEO
2020-09-01
Founder
Stock Details
Investors List
Silicon Valley Bank
Silicon Valley Bank investment in Post-IPO Debt - Candel Therapeutics
H7 Holdings
H7 Holdings investment in Series C - Candel Therapeutics
Level One Partners
Level One Partners investment in Series C - Candel Therapeutics
Sands Capital Ventures
Sands Capital Ventures investment in Series C - Candel Therapeutics
Northpond Ventures
Northpond Ventures investment in Series C - Candel Therapeutics
PBM Capital Group
PBM Capital Group investment in Series B - Candel Therapeutics
National Securities Corporation
National Securities Corporation investment in Series A - Candel Therapeutics
Massachusetts Life Sciences Center
Massachusetts Life Sciences Center investment in Grant - Candel Therapeutics
Key Employee Changes
Official Site Inspections
http://www.candeltx.com Semrush global rank: 4.93 M Semrush visits lastest month: 1.75 K
- Host name: 151.101.130.159
- IP address: 151.101.130.159
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Candel Therapeutics"
About | Candel Therapeutics
At Candel Therapeutics, we are developing viral immunotherapies that are designed to cause in situ vaccination against the unique antigens and neoantigens presented when tumor cells lyse …See details»
Pipeline | Candel Therapeutics
We are evaluating our viral immunotherapies in a variety of solid tumors, including prostate, lung, brain and pancreatic cancer. For more information on our clinical studies, click here.Please visit our Platforms page to learn more about our …See details»
Candel Therapeutics - Crunchbase Company Profile
Candel Therapeutics experienced a significant increase in retail investor interest, with investments rising by 320% last week. The company received FDA Orphan Drug Designation for CAN-2409 for the treatment of pancreatic cancer and …See details»
Candel Therapeutics - LinkedIn
Candel Therapeutics Biotechnology Research Needham, Massachusetts 7,511 followers An off-the-shelf multimodal biological immunotherapy company empowering the patient's immune system to fight cancer.See details»
Candel Therapeutics Appoints Three New Members to its Board of ...
Aug 1, 2022 There, she successfully led the organization to an Initial Public Offering (IPO) and through a significant growth and value creation stage. Mrs. Gaeta has played integral roles …See details»
Candel Therapeutics appoints Diem Nguyen, PH.D., M.B.A., to its …
Jul 15, 2021 Based on the broad range of data that we have generated from our preclinical models and clinical trials using our approach, we have observed what we believe to be a …See details»
Candel Therapeutics - VentureRadar
Similar Companies: Sun BioPharma USA Privately Held Sun BioPharma is developing small-molecule pharmaceuticals consisting of novel polyamine analogues and metal chelators, and …See details»
Candel Therapeutics Reports Third Quarter 2022 Financial Results …
Nov 10, 2022 “Candel made important progress across multiple facets of the organization this quarter,” said Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer of …See details»
Candel Therapeutics - Overview, News & Similar companies
May 16, 2024 Candel Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference NEEDHAM, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- …See details»
Media | Candel Therapeutics
Jul 26, 2021 2021. 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) Phase 1 clinical trial of oncolytic viral immunotherapy with CAN-2409 + valacyclovir in combination with nivolumab and standard of care in …See details»
Batavia and Candel collaborate to develop therapeutics against …
Woburn, MA, March 21, 2024 — Today, Batavia Biosciences, a leading Contract Development and Manufacturing Organization, announces a new partnership with Candel Therapeutics, Inc. …See details»
Release Details - Candel Therapeutics, Inc
Feb 5, 2024 For more information about Candel, visit: www.candeltx.com. Forward-Looking Statements. This press release includes certain disclosures that contain “forward-looking …See details»
Contact | Candel Therapeutics
Want to get in touch with Candel Therapeutics? Reach out today. Address. 117 Kendrick St, Suite 450 Needham, MA 02494See details»
Candel Therapeutics Reports Fourth Quarter and Full Year 2022 …
Mar 30, 2023 For more information about Candel, visit www.candeltx.com. About CAN-2409. CAN-2409, Candel’s most advanced viral immunotherapy candidate, is a replication-defective …See details»
Careers | Candel Therapeutics
Biotech companies have recently been made aware of a growing number of email scams targeting job candidates in our industry. Any emails you receive from Candel Therapeutics will …See details»
Candel Therapeutics Inc (CADL) Stock Price & News - Google
Get the latest Candel Therapeutics Inc (CADL) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.See details»
Release Details - Candel Therapeutics, Inc
May 19, 2023 Treatment with CAN-3110 in arm A showed encouraging median overall survival rate at 11.8 months after a single injection. These data are supported by independent cohort …See details»
Candel Therapeutics Reports First Quarter 2022 Financial Results …
Mar 31, 2022 Cash position bolstered through debt financing to support operations into the fourth quarter of 2023. NEEDHAM, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Candel …See details»
Login | Candel Therapeutics
Only fill in if you are not human. Keep me signed in. RegisterSee details»